home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

282 rows where filing_period = "second_quarter", filing_year = 2018 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 282 ✖

filing_year 1

  • 2018 · 282 ✖

filing_period 1

  • second_quarter · 282 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2139597 ACG ADVOCACY 550104f5-fad6-4271-872e-e28b06aeb8cb 2T ACG ADVOCACY 2057 ROIVANT SCIENCES, INC. 2018 second_quarter PHA Drug Pricing. Innovation Issues. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2018-06-29T13:56:42.033000-04:00
2139890 SIMS STRATEGIES, LLC b3d32ba9-f00a-49d5-bb5a-96744e8e5eea Q2 SIMS STRATEGIES, LLC 401104546 AMAG PHARMACEUTICAL 2018 second_quarter PHA Education on products and issues related to women's health. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-02T13:59:20.760000-04:00
2139894 SIMS STRATEGIES, LLC d4137da8-b534-474b-b17d-6f57bde6ecb3 Q2 SIMS STRATEGIES, LLC 401104546 GLAXOSMITHKLINE, INC. 2018 second_quarter PHA Education and importance of various pharmaceutical industry issues, including issues affecting vaccines. SENATE 40000   0 0 2018-07-02T14:02:24.463000-04:00
2140937 CHATMAN, LLC e0ee2783-0f8c-490c-bfc5-03fc2a4882c4 Q2 CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2018 second_quarter PHA Support continuation of Pharmacy 340B program in HRSA. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-07-08T22:33:50.067000-04:00
2140980 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER afd75a50-5f71-4808-acba-2c9381020ca4 Q2 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2018 second_quarter PHA 340B drug pricing, PREA, CAR-T Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   52635 0 0 2018-07-09T10:41:45.093000-04:00
2141153 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 9044ccfd-ffd6-4b08-a6dd-95d792120d95 Q2 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2018 second_quarter PHA FDA Listening Session on Compounding Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES   10000 0 0 2018-07-09T14:56:20.210000-04:00
2141215 THE METROHEALTH SYSTEM 484fe8a3-543d-4e8c-ae76-8ca8c172c9ce Q2 THE METROHEALTH SYSTEM 288236 THE METROHEALTH SYSTEM 2018 second_quarter PHA 340B HOUSE OF REPRESENTATIVES,SENATE   7500 0 0 2018-07-09T16:06:24.423000-04:00
2141252 AMERICAN CAPITOL GROUP 2cdf0715-a9b2-43b7-a618-060bf92aac4a Q2 AMERICAN CAPITOL GROUP 305852 CARDINAL HEALTH 2018 second_quarter PHA Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2018-07-09T16:35:56.473000-04:00
2141408 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ad8b1f52-6f07-4d57-85ff-e945c161659f Q2 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2018 second_quarter PHA Compounding of radiopharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   30000 0 0 2018-07-10T09:14:04.747000-04:00
2141594 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 289ad1b1-c233-4448-9995-2f69857f4025 Q2 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2018 second_quarter PHA Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2018-07-10T11:50:13.263000-04:00
2141776 AMERICAN COLLEGE OF CLINICAL PHARMACY 78d3484b-36d1-4e62-8af4-f91cdfdc35f8 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2018 second_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2018-07-10T15:03:15.193000-04:00
2142003 HOLLAND & KNIGHT LLP d86d1c92-11bd-4e05-8c0b-a4e76dc15a1b Q2 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2018 second_quarter PHA Advocating for policy to ensure patient access to pain relief; H.R. 664, Stop OD Act of 2017; S.1554, Safer Prescribing of Controlled Substances Act; H.R. 3964, Opioid Addiction Prevention Act of 2017; H.R. 2063, Opioid PACE Act of 2017. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2018-07-11T09:10:07.070000-04:00
2142008 HOLLAND & KNIGHT LLP e800053c-1a7a-415f-bfa3-1bfee0262f94 Q2 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2018 second_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2018-07-11T09:19:11.633000-04:00
2142403 RED+BLUE STRATEGIES 5eb546a3-9290-464d-b966-2615f78cfe9a Q2 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2018 second_quarter PHA S. 2553 - Know the Lowest Price Act of 2018- Support of the elimination of "gag clauses" in Medicare Part D. S. 2554 - Patient Right to Know Act - Support of the elimination of "gag clauses" in private market drug benefits. H.R. 6 - Support for Patients and Communities Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 3120 - Helping to End Addition and Lessen Substance Use Disorders Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 2460/H.R. 3528 - Every Prescription Conveyed Securely Act - support for a bill that would require electronic prescribing for opioids. CMS regulations related to the Medicare Part D program and role of Prescription Drug Plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. The Trump Administration's Blueprint for Controlling Prescription Drug Prices - Issues related to the role PBMs can play in controlling the price of prescription medications in the United States. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-07-11T14:19:48.077000-04:00
2142475 RED+BLUE STRATEGIES 6734889f-147f-47ab-b003-898c4db37d1b Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2018 second_quarter PHA H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions. H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety. S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program. S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs). S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-07-11T14:51:17.677000-04:00
2142506 KOUNTOUPES DENHAM CARR & REID, LLC 3aab16f3-edc1-4dc8-bb82-ccb8b987ed62 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2018 second_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-11T15:12:58.163000-04:00
2142509 RED+BLUE STRATEGIES 5d6ec848-ca51-40b7-ab06-488767191cc8 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2018 second_quarter PHA H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on public health. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on public health. S. 2315 - The Over the Counter Drug Safety Innovation and Reform Act - Support for amending and improving OTC Monograph Reform. S. 2852 - the Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to the continues attention required to antibiotic resistance as a public health threat and policies to ensure the adequacy and development of antibiotics to ward against threats to the common good. Trump Administration's Blueprint for lowering the price of prescription medications in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to over the counter medications and supplements. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 30000   0 0 2018-07-11T15:12:59.600000-04:00
2142781 APOTEX CORP. e91b492c-3c69-40e2-8f70-82ef2d73a690 Q2 APOTEX CORP. 310973 APOTEX CORP. 2018 second_quarter PHA S. 974/H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods; Federal policy relating to the Trump Administration's Fiscal Year 2019 Budget proposal to address pharmaceutical market blockages caused by parked Hatch-Waxman 180 day exclusivity periods; S. 124, the Preserve Access to Affordable Generics Act, provisions relating to pharmaceutical patent settlements between generic and brand drug manufacturers; and Federal policy relating to the impact of rebates on the development of the biosimilars market. HOUSE OF REPRESENTATIVES,SENATE   160000 0 0 2018-07-12T09:42:19.997000-04:00
2142898 TAUZIN STRATEGIC NETWORKS 13a911f7-dbee-49ff-96dc-7d4da5caea73 Q2 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2018 second_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-12T11:20:39.507000-04:00
2142971 BROWN RUDNICK LLP a72d2d6f-2e91-4d22-b746-32ada8cd5254 Q2 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2018 second_quarter PHA Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-07-12T11:56:32.697000-04:00
2143054 BROWN RUDNICK LLP ebf39b3f-bda8-48bb-afdc-761129fa423e Q2 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2018 second_quarter PHA S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-12T13:30:34.787000-04:00
2143252 KOUNTOUPES DENHAM CARR & REID, LLC 65dbf30f-1415-4975-a832-abf2079c834c Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2018 second_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 and S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-12T16:09:25.767000-04:00
2143288 KOUNTOUPES DENHAM CARR & REID, LLC 3ad05305-318d-46db-bf80-77f77fb9ef9a Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2018 second_quarter PHA General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Proactive measures to curb opioid abuse, including H. R. 3528, Every Prescription Conveyed Securely Act, and H. R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of the Vice President of the United States,SENATE,White House Office 50000   0 0 2018-07-12T16:45:54.800000-04:00
2143338 KOUNTOUPES DENHAM CARR & REID, LLC e81bebdd-7d53-46a5-a176-888f5a7ef1fb Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2018 second_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-12T17:36:27.790000-04:00
2143347 ACADEMY OF MANAGED CARE PHARMACY a13144f9-c7b6-43f1-8ac5-c19d0452c43c Q2 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2018 second_quarter PHA Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. HOUSE OF REPRESENTATIVES,SENATE   85000 0 0 2018-07-12T18:16:36.407000-04:00
2143394 MCDERMOTT+ LLC 3158c8a3-6576-4fe4-9431-bcca499c60a6 Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2018 second_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-07-13T08:59:11.907000-04:00
2143463 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 99387ac3-74f5-4a5a-aa57-22077cf02108 Q2 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2018 second_quarter PHA HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HR 6082 Overdose Prevention and Patient Safety Act; support treatment options/funding for reduction and treatment of opioid addiction. HOUSE OF REPRESENTATIVES,SENATE   10452 0 0 2018-07-13T10:09:00.450000-04:00
2143515 MS. TAMI WAHL d9625fe6-46dc-456e-8b4f-4121ff868ce3 Q2 MS. TAMI WAHL 401104405 ROCK & ASSOCIATES 2018 second_quarter PHA Legislation impacting the operation of pharmacy compounding, and access to compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-07-13T10:40:36.687000-04:00
2143775 KOUNTOUPES DENHAM CARR & REID, LLC c6f0a95a-9e81-45c2-a457-5c7085445712 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2018 second_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 2212 and S.974, the CREATES Act of 2017, and H. R. 2051, the Fair Access for Safe and Timely Generics (FAST) Generics Act of 2017. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of the Vice President of the United States,SENATE,White House Office 60000   0 0 2018-07-13T12:39:35.513000-04:00
2143979 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 3f41dcd1-ca24-4921-85ff-be7414bd576e Q2 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2018 second_quarter PHA Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval Commerce, Dept of (DOC),Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,State, Dept of (DOS),Treasury, Dept of   420000 0 0 2018-07-13T15:16:47.237000-04:00
2144254 LINCOLN PARK GROUP L.L.C. 5dc944ad-7aa0-4944-b2e8-52f25b5567dc Q2 LINCOLN PARK GROUP L.L.C. 401104374 PD FRAZER CONSULTING, INC. ON BEHALF OF CANADA INTERNATIONAL PHARMACY ASSOC. 2018 second_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act; HR 5752 Stop Illicit Drug Importation Act. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-07-13T18:01:39.083000-04:00
2144275 ASCENSION HEALTH 8fa71f98-0268-48e3-afdd-c093324e5141 Q2 ASCENSION HEALTH 53301 ASCENSION HEALTH 2018 second_quarter PHA Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES) FAIR Drug Pricing Act; Drug pricing; 340B Drug Discount Program; Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)   390000 0 0 2018-07-13T21:17:07.513000-04:00
2144455 CONNECT 4 STRATEGIES, LLC fd376fc9-12cf-4752-90ca-9fbf8a96d471 Q2 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2018 second_quarter PHA s916 Access to Emergency Medications Act Medication assisted therapy - opioids Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-15T09:19:03.450000-04:00
2144503 INDEPENDENT PHARMACY COOPERATIVE cebf9726-4632-4aee-9c89-51e1cf926137 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2018 second_quarter PHA Medicare CONTRACT YEAR 2019 POLICY AND TECHNICAL CHANGES comments. Support all drug price concessions at the point of sale. Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2018-07-15T15:59:48.480000-04:00
2144651 MCDERMOTT WILL & SCHULTE LLP c41b5d6b-03ab-45b7-bb59-cdee5f64a3c1 Q2 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2018 second_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 50000   0 0 2018-07-16T09:55:31.357000-04:00
2144775 CAPITOL STRATEGIES GROUP, LLC 5dfcf045-56e6-4606-ac8e-921cc84ac3d1 Q2 CAPITOL STRATEGIES GROUP, LLC 400462294 PHRMA (ON BEHALF OF WE WORK FOR HEALTH ) 2018 second_quarter PHA Medical Innovation, Medicare Part B and and IPAB HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-07-16T10:30:41.283000-04:00
2144958 THE KUTLER GROUP d41936fd-3443-41bb-87f6-d0fb9d4ef0e6 Q2 THE KUTLER GROUP 401103966 PRIME THERAPEUTICS 2018 second_quarter PHA Patient Right to Know Drug Prices Act Prescription Transparency Act CREATES Act HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2018-07-16T11:57:40.083000-04:00
2145130 ACADEMY OF MANAGED CARE PHARMACY 34daf584-f4b1-435b-87e5-1a46fbc46208 2A ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2018 second_quarter PHA Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   85000 0 0 2018-07-16T12:53:22.087000-04:00
2145354 KATE MOSS a8aa941e-19d9-465f-90e7-57d2eca8fdae Q2 KATE MOSS 25988 CVS HEALTH 2018 second_quarter PHA Legislation impacting PBMs and drug pricing HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-07-16T14:26:07.193000-04:00
2146007 COVINGTON & BURLING LLP a21baaab-a3ce-4a40-8bd8-f6a0f0cd38c5 Q2 COVINGTON & BURLING LLP 11195 FLEXION THERAPEUTICS, INC. 2018 second_quarter PHA Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies, including FDA Opioid Sparing legislation. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-07-16T19:58:11.467000-04:00
2146044 BROYDRICK & ASSOCIATES 82c4fb08-f794-470e-ad18-b232e762fdaa Q2 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2018 second_quarter PHA Drug shortages and FDA approval, USTR acceptance. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-16T22:00:42.973000-04:00
2146059 BROYDRICK & ASSOCIATES 55ab0fa2-b224-4604-b5b9-cf2fb0128b8a Q2 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2018 second_quarter PHA Funding for a new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-07-16T22:25:57.913000-04:00
2146669 PENN AVENUE PARTNERS c326e8f9-b93e-4efe-b9e7-f5730ae07a48 Q2 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2018 second_quarter PHA Regulatory and legislative issues impacting Alkermes. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-17T11:21:59.680000-04:00
2147211 PENN AVENUE PARTNERS 6df2a6d7-431d-4b31-8a40-fbea42aa0392 Q2 PENN AVENUE PARTNERS 400918672 PURDUE PHARMA L.P. 2018 second_quarter PHA Monitoring legislative and regulatory activities impacting the pharmaceutical industry. SENATE 60000   0 0 2018-07-17T13:28:37.180000-04:00
2147363 OREGON HEALTH & SCIENCE UNIVERSITY b25b329b-5289-4d82-b83c-4ec925079963 Q2 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2018 second_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2018-07-17T13:56:06.293000-04:00
2147542 PUBLIC CITIZEN 0d7bd05b-7e8f-4523-882f-20fc8c940e33 Q2 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2018 second_quarter PHA S 2011/HR 4138-Medicare Drug Price Negotiation Act, S 974/HR 2212-CREATES Act of 2017, S 124-Preserve Access to Affordable Generics Act, HR 1625-OMNIBUS, opioid addiction data analysis, S 771-Improving access to affordable prescription drugs act, S 252-Medicare Drug Savings act of 2017, S 1369-Stop Price Gouging Act, S 495-Medical innovation and prize fund act, S 1131/HR 2439-FAIR drug pricing act, HR 4117-Competitive Drugs act of 2017, S 771/HR 1776-Improving access to affordable prescription drugs act, S 637-C-THRU Act, S 1347-RxCap Act of 2017, S 1348-SPIKE Act of 2017, HR 5156-Protecting Medicare from Excessive Price Increases Act of 2018, S 2691-Opioid Crisis accountability act of 2018, S 2315-Over the counter drug safety, innovation, and reform act, S 2700/HR 5545-Comprehensive Addiction Resources Emergency (CARE) act, Drug Pricing-Medicare Part D HR 2051-FAST Generics Act of 2017, HR 4116-Transparent Drug Pricing Act, S 2852-Pandemic and All-Hazards Preparedness Act and advancing innovative Act of 2018, HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   70000 0 0 2018-07-17T14:23:14.657000-04:00
2147596 MERCY HEALTH SYSTEM 89d61425-9096-42cb-9c40-4b3076d7a116 Q2 MERCY HEALTH SYSTEM 40043344 MERCY HEALTH SYSTEM 2018 second_quarter PHA Palliative Care 340 B Drug program Health Care Reform HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-07-17T14:30:34.390000-04:00
2147695 MEHLMAN CONSULTING, INC. 990fee3e-cf44-49b1-a2d8-981067f3bb72 Q2 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2018 second_quarter PHA Issues related to health insurance and prescription drug pricing. S. 974 - The CREATES Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-17T14:59:34.807000-04:00
2147784 ICE MILLER LLP 37908d21-7472-4b71-99db-bc1cf78d32fd Q2 ICE MILLER LLP 67854 ELI LILLLY AND COMPANY 2018 second_quarter PHA Issues related to pharmaceutical research and manufacturing Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE,Vice President of the U.S.     0 0 2018-07-17T15:13:13.660000-04:00
2147886 HANCE SCARBOROUGH 30e80492-40c9-4554-be26-2bb65b743eae Q2 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2018 second_quarter PHA Issues related to the regulation of pharmacy compounding. HR2871 Preserving Patient Access to Compounded Mediations Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-07-17T15:30:02.983000-04:00
2148020 FLYNN & ASSOCIATES, INC. aca730de-5b84-48dd-8139-3a31cc60ae8c Q2 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2018 second_quarter PHA Childrens Health Insurance Program Importation of drugs from Canada Medicare Part D - Rebates HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-07-17T15:49:05.737000-04:00
2148026 HANCE SCARBOROUGH 6a2dcf83-b335-439e-a9c7-477a418cec59 Q2 HANCE SCARBOROUGH 17443 TITAN PHARMACEUTICALS, INC. 2018 second_quarter PHA Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018. HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-07-17T15:50:07.813000-04:00
2148560 THE D MAJOR GROUP 52f22542-dd19-47f9-a33b-74034852d9f5 Q2 THE D MAJOR GROUP 401103162 ALLERGAN INC (FORMERLY ACTAVIS INC ) 2018 second_quarter PHA Monitor issues concerning bioequivalence standards for pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-17T19:28:41.700000-04:00
2148841 MERCURY PUBLIC AFFAIRS, LLC 82ee7781-af3e-48d6-b022-deeec865f56d 2T MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2018 second_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 20000   0 1 2018-07-18T08:54:09.487000-04:00
2149339 MERCURY PUBLIC AFFAIRS, LLC e9f00320-32ec-4ae8-b40b-9ece5784f864 Q2 MERCURY PUBLIC AFFAIRS, LLC 70175 MORRIS AND DICKSON 2018 second_quarter PHA IT Help RE Improper Prescriptions Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),Justice, Dept of (DOJ),Office of Natl Drug Control Policy (NDCP),White House Office 20000   0 0 2018-07-18T10:39:18.023000-04:00
2149353 BALLARD PARTNERS f01d355d-19f5-4125-b7d8-c47accf8e734 Q2 BALLARD PARTNERS 401104288 LABORATORY CORPORATIONS OF AMERICA HOLDINGS 2018 second_quarter PHA Clinical Lab Rates White House Office 80000   0 0 2018-07-18T10:41:24.023000-04:00
2149480 LUPIN PHARMACEUTICALS INC 84d3cf1b-7bd4-474f-841b-acc48288b066 Q2 LUPIN PHARMACEUTICALS INC 401104766 LUPIN PHARMACEUTICALS INC 2018 second_quarter PHA CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis. HOUSE OF REPRESENTATIVES,SENATE   99267 0 0 2018-07-18T10:57:17.273000-04:00
2149730 HUSCH BLACKWELL, LLP 928628ca-2c6c-444f-bdd4-62152ac657b0 Q2 HUSCH BLACKWELL, LLP 6303 ARJ INFUSION SERVICES, INC. 2018 second_quarter PHA Issues related to home infusion therapy; S.1738 HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-07-18T11:35:22.777000-04:00
2149909 BALLARD PARTNERS 682d76e9-d3e6-485e-8b52-a7884f22787b Q2 BALLARD PARTNERS 401104288 THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) 2018 second_quarter PHA 340B Drug Discount Program   10000   0 0 2018-07-18T12:12:59.860000-04:00
2149943 PRIME THERAPEUTICS 0aac680c-7183-4d9b-9a27-78b6936b6249 Q2 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2018 second_quarter PHA H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines. S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2018-07-18T12:21:23.753000-04:00
2150360 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 272f7e14-9aa5-4f4c-b8af-337d3eb2a996 Q2 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2018 second_quarter PHA Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-18T14:10:26.717000-04:00
2150410 MANATT, PHELPS, AND PHILLIPS 039c1baf-df73-446b-a8db-370adfad8867 Q2 MANATT, PHELPS, AND PHILLIPS 23645 NEKTAR THERAPEUTICS 2018 second_quarter PHA FDA oversight of certain pain reliever products Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 21600   0 0 2018-07-18T14:21:55.453000-04:00
2150654 MASSACHUSETTS MEDICAL SOCIETY 29f771f8-cc95-4f89-a75e-ee270ff31e05 Q2 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2018 second_quarter PHA S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2018-07-18T15:03:50.067000-04:00
2151054 THORSEN FRENCH ADVOCACY LLC 7ed84331-ed97-4676-9373-6a54d23e8994 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 CARDINAL HEALTH, INC. 2018 second_quarter PHA Issues related to prescription drug abuse. Issues related to pharmaceutical market value. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-18T15:55:33.340000-04:00
2151078 THORSEN FRENCH ADVOCACY LLC 9ca15a68-f7dc-4871-8c47-83f0ae8aabaf Q2 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2018 second_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-18T15:58:46.577000-04:00
2151110 THORSEN FRENCH ADVOCACY LLC 45f1382b-a0d7-4f80-9b84-5831ffd66901 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2018 second_quarter PHA Issues related to pharmaceutical market value. Issues related to prescription drug abuse. H.R.2212: CREATES Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-18T16:01:04.387000-04:00
2151297 ROCK & ASSOCIATES 710f6e76-c03b-4a78-b0af-2dc397f3d0cb Q2 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:22:17.483000-04:00
2151301 ROCK & ASSOCIATES e01ba4c5-6e96-46cb-a446-3c3fdc02d3cc Q2 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:23:22.093000-04:00
2151312 ROCK & ASSOCIATES 1ccd3a09-5cd6-41fa-b1dc-503f5ece4300 Q2 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:24:26.140000-04:00
2151323 ROCK & ASSOCIATES 6023a7ba-4dea-4aa8-95f3-5e4504492e48 Q2 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:25:33.173000-04:00
2151341 ROCK & ASSOCIATES 173e6190-ed62-4f0e-a672-f047a547b806 Q2 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:26:42.860000-04:00
2151360 ROCK & ASSOCIATES 91d44697-aafd-48a7-b577-36ec738eeaee Q2 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:27:51.093000-04:00
2151369 ROCK & ASSOCIATES c6c3ec8d-5a75-4b3a-9178-a8d1372305f4 Q2 ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2018 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-07-18T16:28:54.173000-04:00
2151410 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION d3544e17-df36-45cd-8b73-8a1de58c84b9 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2018 second_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   255000 0 0 2018-07-18T16:34:09.750000-04:00
2151856 ACG ADVOCACY c3cc4c8d-332b-44ba-b899-743068779d75 Q2 ACG ADVOCACY 2057 WALGREEN CO. 2018 second_quarter PHA Competition Policy Issues. Drug Pricing Policy Issues. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-07-18T17:35:59.727000-04:00
2151949 WEST FRONT STRATEGIES LLC 572189b6-cfcf-4dd8-9aab-f20a8e8f7a0c Q2 WEST FRONT STRATEGIES LLC 401103493 WALGREEN CO. 2018 second_quarter PHA Pharmacy and Medically Underserved Areas Enhancement Act (S. 109 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas; issues related to opioids; H.R. 3528 and S. 2460, the "Every Prescription Conveyed Securely Act." HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-07-18T17:45:34.667000-04:00
2152032 HOOPER, LUNDY & BOOKMAN, P.C. 92683c5b-e7cb-4e3a-9bf0-56bca99ce957 Q2 HOOPER, LUNDY & BOOKMAN, P.C. 401020884 BROWN RUDNICK, LLP, ON BEHALF OF PRIME THERAPEUTICS 2018 second_quarter PHA H.R. 5343-Prescription Transparency Act of 2018; S. 2554-Patient Right to Know Drug Prices Act HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-07-18T18:09:20.823000-04:00
2152397 RAMPY NORTHRUP LLC a1102fd5-e517-4f2f-b0fc-cd9e572120ff Q2 RAMPY NORTHRUP LLC 401103289 ACADEMY OF MANAGED CARE PHARMACY 2018 second_quarter PHA Dissemination of pharmacoeconomic information. Implementation of 21st Century Cures Act (P.L.114-255). H.R.2026, Pharmaceutical Information Exchange Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-18T21:55:41.180000-04:00
2152448 GREENBERG TRAURIG, LLP 9b581e8d-f6c6-40e7-9c5b-5c07f1e0489c Q2 GREENBERG TRAURIG, LLP 16896 VHG LABS, INC. 2018 second_quarter PHA Administrative and legislative monitoring and outreach on issues related to pharmaceutical reference standards. Food & Drug Administration (FDA),SENATE 60000   0 0 2018-07-18T22:17:05.997000-04:00
2152493 THORN RUN PARTNERS ba16267e-73c8-45ba-98a4-a1379547739f Q2 THORN RUN PARTNERS 400534596 EXPRESS SCRIPTS, INC. 2018 second_quarter PHA Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-18T22:45:32.733000-04:00
2152743 BUCHANAN INGERSOLL & ROONEY PC b6646789-5c84-4ae7-a86a-ac7481daaff8 Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 ANI PHARMACEUTICALS, INC. 2018 second_quarter PHA Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA. Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-19T05:51:08.167000-04:00
2152755 BUCHANAN INGERSOLL & ROONEY PC 6a17de15-4dcc-4677-a9b9-a76a20b343c5 Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 LIPOCINE 2018 second_quarter PHA Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-07-19T06:02:14.670000-04:00
2152770 BUCHANAN INGERSOLL & ROONEY PC 4566c26e-87e8-4c56-a1e9-ea71bf3a9c6b Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 NOVUM PHARMA 2018 second_quarter PHA Federal government relations service and strategy relating to pricing issues affecting the pharmaceutical industry Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-19T06:22:21.953000-04:00
2152874 VAN SCOYOC ASSOCIATES 6aa0a19f-e5a8-4cea-8322-23853722b47e Q2 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2018 second_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-07-19T08:12:05.263000-04:00
2152931 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. e4360ff6-9dae-4f62-a264-e99a4ea0a098 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2018 second_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2018-07-19T08:40:31.937000-04:00
2152959 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 16306201-da7e-42e1-8d5e-f8b6da61435a Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2018 second_quarter PHA Issues related to the 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-19T08:43:41.187000-04:00
2152971 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ced4bf17-4f4f-4b85-b6bc-05aa05afc07c Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2018 second_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2018-07-19T08:47:46.563000-04:00
2152976 UC HEALTH 20f2b75c-04a1-455c-86b8-32c075261e82 Q2 UC HEALTH 401103195 UC HEALTH 2018 second_quarter PHA 340b program, drug pricing Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-07-19T08:47:47.703000-04:00
2152984 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 0b196d8b-7749-4f1d-9aca-61139dea2e96 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2018 second_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2018-07-19T08:49:52.720000-04:00
2153261 UNIVERSITY OF IOWA f606de44-3f64-44de-946d-e82fc5dca490 Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2018 second_quarter PHA FY 19 appropriations for NIH Support for 340B program Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)   40000 0 0 2018-07-19T09:57:52.447000-04:00
2153783 FTI GOVERNMENT AFFAIRS 12254b2d-7c89-4ee1-87c0-e5db5d4f6ac5 Q2 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2018 second_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-07-19T10:52:55.860000-04:00
2153846 GREATER NEW YORK HOSPITAL ASSOCIATION 5de849e0-3940-40e2-af47-f9ffdea65a6f Q2 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2018 second_quarter PHA Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support) Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Raise awareness about injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Supported legislation to increase competition in the drug marketplace, the CREATES Act (S. 974) (support) Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   610000 0 0 2018-07-19T10:57:22.563000-04:00
2154023 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 16e4547a-d793-41a9-a8b5-a2b5c853e79e Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2018 second_quarter PHA Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Opioid Abuse - General issues related to opioid abuse (HR6, S 2838, S 2837, S 3120, S 2680); Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   327990 0 0 2018-07-19T11:12:53.517000-04:00
2154532 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION d5fb409d-678d-47d0-81c3-0db7b7d95006 Q2 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 31348 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2018 second_quarter PHA Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues included in the Proposed Part D Rule and accompanying RFI. Issues related to Medicaid Provider Enrollment. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Issues related to pharmacy gag clauses. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act S.2553/H.R.6144, Know the Lowest Price Act of 2018 S.2554/H.R.6143, Patient Right to Know Drug Prices Act H.R.5343, Prescription Transparency Act of 2018 H.R.4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018 Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE   766889 0 0 2018-07-19T11:52:15.007000-04:00
2155151 FORBES-TATE 99778def-a5e3-44c6-90ce-35b112694e34 Q2 FORBES-TATE 400976792 PHRMA 2018 second_quarter PHA Issues pertaining to Rx Drug pricing. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-07-19T12:59:53.460000-04:00
2155500 ACG ADVOCACY 7af34ab0-a302-4d86-a90e-bf5fda6afca0 Q2 ACG ADVOCACY 2057 GENENTECH INC 2018 second_quarter PHA Drug pricing issues. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-07-19T13:27:00.807000-04:00
2155571 WINNING STRATEGIES WASHINGTON b21ff906-fe7b-4d76-9cf4-b1fa14efa317 Q2 WINNING STRATEGIES WASHINGTON 50796 KALEO 2018 second_quarter PHA Pharmaceutical drug development including epinephrine for anaphylaxis Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-07-19T13:32:33.103000-04:00
2155708 POLARIS GOVERNMENT RELATIONS, LLC 83bb63e4-2762-4b5b-ad4e-8fda3838e432 Q2 POLARIS GOVERNMENT RELATIONS, LLC 307730 ASSOCIATION FOR ACCESSIBLE MEDICINES 2018 second_quarter PHA Provide advice and counsel on matters impacting the generic pharmaceutical industry such as generic labeling and access; CREATES Act, S. 3056 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-07-19T13:47:32.717000-04:00
2156070 ELI LILLY AND COMPANY 61df05e4-364e-4d49-b49d-9215926adac5 Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2018 second_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1490000 0 0 2018-07-19T14:20:45.610000-04:00
2156393 ACG ADVOCACY 9d5ad850-5797-459b-bd30-c98ac06ee415 Q2 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2018 second_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-07-19T14:41:30.050000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1906.245ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API